Hutchison China MediTech Limited
Hutchison China MediTech Limited (HCM) is a clinical‑stage biopharmaceutical company focused on discovering, developing and commercialising targeted therapies in oncology and immunology. Headquartered in China and listed on public markets, HCM’s value largely depends on the progress of its research and late‑stage clinical trials, regulatory decisions and licensing partnerships rather than steady product revenues. Investors should note the company is R&D‑intensive: potential upside comes from successful trial readouts, approvals or deal‑making, while downside can follow setbacks, delays or adverse results. Market cap sits around $2.67bn, reflecting market expectations for future growth balanced with development risks. For investors this means higher volatility and event‑driven price moves; suitable for those who understand biotech cycles and can tolerate the risk of capital loss. This is general information for education and should not be taken as personal advice.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Hutchison China MediTech's stock with a target price of $27.51, indicating strong growth potential.
Financial Health
Hutchison China MediTech Limited is performing well in revenue and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring HCM
U.S.-China Trade Truce | Investment Opportunities
High-level talks between the U.S. and China are underway to prevent the return of tariffs, a critical step for global economic stability. This creates a potential investment opportunity in companies poised to benefit from improved trade relations and the removal of trade barriers.
Published: September 15, 2025
Explore BasketChina's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketChinese Stocks
Looking to tap into the world's second-largest economy? This carefully selected collection features China's most promising companies, handpicked by professional analysts for their growth potential. From tech giants to consumer leaders, these stocks offer direct access to China's economic powerhouse.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical‑stage pipeline
Progress in late‑stage trials can drive value, though outcomes are binary and share prices may swing sharply after results.
Deal‑making potential
Licensing or partnership agreements can unlock near‑term cash and validation, but reliance on partners adds execution risk.
China market exposure
Presence in China offers large patient markets and tailored regulatory pathways, yet geographic concentration brings policy and commercial uncertainties.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
